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other analytes (e.g., protein markers) in parallel 
with cfDNA may also enhance early detection.5
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Intravenous Iron in Patients Undergoing Maintenance Hemo-
dialysis (N Engl J Med 2019;380:447-458). A programming error 
led to numerous inaccuracies in the analysis published online 
on October 26, 2018: results for nonfatal myocardial infarction, 
nonfatal stroke, and hospitalization for heart failure had been 
based on investigators’ judgments rather than on adjudicated 
events, and all results for these outcomes are affected. The cor-
rected results based on reanalysis include fewer events and, 
probably because of the exclusion of events rejected by the end 
points committee, the estimated treatment effects are slightly 
enhanced. The slight improvements in the hazard ratio for the 
primary end point result in a new P value of 0.04 for superior-
ity. The composite secondary end point of fatal or nonfatal myo-
cardial infarction was most affected by the error; the new hazard 
ratio for the comparison between the high-dose and the low-
dose groups is 0.69 (95% confidence interval [CI], 0.52 to 0.93). 
For the composite secondary end point of fatal or nonfatal myo-
cardial infarction, fatal or nonfatal stroke, or hospitalization for 
heart failure, the new hazard ratio is 0.80 (95% CI, 0.64 to 
1.00). The key messages from the findings remain unchanged 
in terms of the safety of high-dose intravenous iron. Analyses 
not involving adjudicated myocardial infarction, nonfatal stroke, 
or hospitalization for heart failure are unaffected. The earlier 
version of the article is available with the full text of the new 
version. The article is correct and the Supplementary Appendix 
has been replaced at NEJM.org.
Diverticulitis (N Engl J Med 2018;379:1635-1642). In the Local-
ized Perforation — Uncomplicated Diverticulitis subsection of 
Diagnosis and Evaluation, in the final sentence of the second 
paragraph (page 1639), the expression “single-agent therapy 
with a β-lactam or β-lactamase inhibitor, or meropenem” 
should have read, “single-agent therapy with a β-lactam or 
β-lactam/β-lactamase inhibitor combination, or meropenem.” 
The article is correct at NEJM.org.
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